CL2014002988A1 - Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo. - Google Patents

Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo.

Info

Publication number
CL2014002988A1
CL2014002988A1 CL2014002988A CL2014002988A CL2014002988A1 CL 2014002988 A1 CL2014002988 A1 CL 2014002988A1 CL 2014002988 A CL2014002988 A CL 2014002988A CL 2014002988 A CL2014002988 A CL 2014002988A CL 2014002988 A1 CL2014002988 A1 CL 2014002988A1
Authority
CL
Chile
Prior art keywords
nifedipine
manufacturing
dosage form
pharmaceutical dosage
candesartan cilexetil
Prior art date
Application number
CL2014002988A
Other languages
English (en)
Spanish (es)
Inventor
Peter Kleinebudde
Adrian Funke
GüNTER MEYER
Martina Smikalla
Andreas Meeners
Markus Wirges
Daniela Brock
Sarah Just
Klaus Knop
Jochen Axel Zeitler
Rolf-Anton Boeggering
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002988(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2014002988A1 publication Critical patent/CL2014002988A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2014002988A 2012-05-07 2014-11-04 Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo. CL2014002988A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12167035 2012-05-07
EP13151946 2013-01-18

Publications (1)

Publication Number Publication Date
CL2014002988A1 true CL2014002988A1 (es) 2015-03-13

Family

ID=48289160

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002988A CL2014002988A1 (es) 2012-05-07 2014-11-04 Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo.

Country Status (27)

Country Link
US (1) US9539176B2 (en, 2012)
EP (1) EP2846777B1 (en, 2012)
JP (1) JP6231553B2 (en, 2012)
KR (1) KR20150007297A (en, 2012)
CN (1) CN104507459A (en, 2012)
AR (1) AR090940A1 (en, 2012)
AU (1) AU2013258273A1 (en, 2012)
BR (1) BR112014027618A2 (en, 2012)
CA (1) CA2872542A1 (en, 2012)
CL (1) CL2014002988A1 (en, 2012)
CO (1) CO7190241A2 (en, 2012)
CR (1) CR20140511A (en, 2012)
DO (1) DOP2014000251A (en, 2012)
EA (1) EA201492026A1 (en, 2012)
EC (1) ECSP14025965A (en, 2012)
ES (1) ES2612532T3 (en, 2012)
GT (1) GT201400245A (en, 2012)
HK (1) HK1204292A1 (en, 2012)
IL (1) IL235040A0 (en, 2012)
IN (1) IN2014DN09045A (en, 2012)
MX (1) MX2014013320A (en, 2012)
PE (1) PE20142284A1 (en, 2012)
PH (1) PH12014502469A1 (en, 2012)
SG (1) SG11201406363VA (en, 2012)
TW (1) TW201410266A (en, 2012)
UY (1) UY34786A (en, 2012)
WO (1) WO2013167453A1 (en, 2012)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9244004B2 (en) * 2013-08-08 2016-01-26 Stichting Sron—Netherlands Institute For Space Research Method and system for inspection of composite assemblies using terahertz radiation
US10071482B2 (en) 2015-08-19 2018-09-11 Ford Global Technologies, Llc Robotic vehicle painting instrument including a terahertz radiation device
US10365229B2 (en) * 2015-12-31 2019-07-30 Kaiser Optical Systems, Inc. Real-time characterization of pharmaceutical tablet coatings using Raman spectroscopy
DE102016222667A1 (de) * 2016-11-17 2018-05-17 Robert Bosch Gmbh Verfahren zum Betrieb einer Anlage zum Herstellen von pharmazeutischen Produkten
US10323932B1 (en) 2017-12-28 2019-06-18 Ford Motor Company System for inspecting vehicle bodies
JP7263047B2 (ja) 2019-02-25 2023-04-24 沢井製薬株式会社 フィルムコーティング錠剤
CN110411978B (zh) * 2019-07-26 2020-05-22 中国农业大学 一种物料均匀性检测设备及检测方法
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670827C3 (de) 1967-03-20 1974-10-24 Bayer Ag, 5090 Leverkusen 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4426019A (en) 1981-10-15 1984-01-17 The Coca-Cola Company Membrane seal and knife combination for a post-mix beverage dispensing system
US4576604A (en) 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
EP0386440B1 (de) 1989-02-11 1992-08-05 Bayer Ag Arzneimittel mit kontrollierter Wirkstoffabgabe
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5656650A (en) 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
WO1992010097A1 (en) 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5178867A (en) 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
CA2368367A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of methylphenidate
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
EP1413315A4 (en) 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
CA2464561A1 (en) 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
WO2003080057A1 (fr) 2002-03-27 2003-10-02 Bayer Aktiengesellschaft Comprime-noyau de taille reduite contenant de la nifedipine
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
PT1558220E (pt) 2003-07-24 2010-03-12 Rasendrakumar Jha Composições orais para tratamento da diabetes
EP1711168A2 (en) 2004-01-23 2006-10-18 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
WO2005070398A2 (en) 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
WO2005084648A1 (en) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
TW200534879A (en) 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100978592B1 (ko) 2005-05-10 2010-08-27 테바 파마슈티컬 인더스트리즈 리미티드 안정한 미세 분말 칸데사탄 실렉세틸 및 이것의 제조 방법
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
JP5039135B2 (ja) 2006-07-03 2012-10-03 ノボ・ノルデイスク・エー／エス 注射器具のための接続
KR100888131B1 (ko) 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
WO2008045006A1 (en) 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
WO2008065097A2 (en) 2006-11-28 2008-06-05 Laboratorios Liconsa, S.A. Stabilized solid pharmaceutical composition of candesartan cilexetil
WO2009054550A1 (en) 2007-10-25 2009-04-30 Bayer Yakuhin, Ltd. Nifedipine-containing press coated tablet and method of preparing the same
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US20130224296A1 (en) 2010-09-03 2013-08-29 Bristol-Myers Squibb Company Drug Formulations Using Water Soluble Antioxidants

Also Published As

Publication number Publication date
PH12014502469A1 (en) 2014-12-22
BR112014027618A2 (pt) 2017-06-27
CR20140511A (es) 2014-12-02
KR20150007297A (ko) 2015-01-20
MX2014013320A (es) 2015-08-10
EP2846777A1 (en) 2015-03-18
HK1204292A1 (en) 2015-11-13
AU2013258273A1 (en) 2014-11-13
SG11201406363VA (en) 2014-11-27
JP6231553B2 (ja) 2017-11-15
IN2014DN09045A (en, 2012) 2015-05-22
DOP2014000251A (es) 2014-12-31
WO2013167453A1 (en) 2013-11-14
GT201400245A (es) 2015-08-25
EA201492026A1 (ru) 2015-09-30
US20130309302A1 (en) 2013-11-21
ES2612532T3 (es) 2017-05-17
AR090940A1 (es) 2014-12-17
EP2846777B1 (en) 2016-10-26
UY34786A (es) 2013-11-29
ECSP14025965A (es) 2015-12-31
IL235040A0 (en) 2014-12-31
CA2872542A1 (en) 2013-11-14
CO7190241A2 (es) 2015-02-19
JP2015515999A (ja) 2015-06-04
PE20142284A1 (es) 2014-12-17
US9539176B2 (en) 2017-01-10
CN104507459A (zh) 2015-04-08
TW201410266A (zh) 2014-03-16

Similar Documents

Publication Publication Date Title
CL2014002988A1 (es) Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo.
NL301197I2 (nl) daridorexant of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder daridorexanthydrochloride
NL301323I2 (nl) acoramidis en/of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder acoramidishydrochloride
CL2014003306A1 (es) Preparacion farmaceutica oral que comprende un inhibidor de tirosina quinasa de bruton y forma cristalina a del mismo.
NL301280I2 (nl) Rezafungin of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder rezafunginacetaat
NL300947I2 (nl) Bictegravir of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bictegravirnatrium
ME03090B (me) Pirazolamidni spoj i njegova upotreba u medicini
BR112014031522A2 (pt) métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
IL242126B (en) Compounds comprising a modified oligonucleotide and a conjugate group
SMT201500209B (it) Forme di dosaggio farmaceutiche a rilascio controllato
PL3424955T3 (pl) Metoda wytwarzania koniugatu przeciwciało-lek anty-trop2
PL2919766T3 (pl) Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
IL228925A0 (en) Benzothiazole compounds and their pharmaceutical use
CO6821948A2 (es) Tableta a prueba de alteración que proporciona liberación inmediata del fármaco
CO6811869A2 (es) Tableta a prueba de manipulación que proporciona liberación de fármaco inmediato
BR112013014361A2 (pt) forma de dosagem
DK2894151T3 (da) Imidazolinderivater, fremgangsmåder til fremstilling deraf og anvendelse deraf i medicin
ZA201603272B (en) Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
CO6791611A2 (es) Tableta dispersable en forma oral
EP2998296A4 (en) Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
CO6940408A2 (es) Composiciones en forma de comprimido de disolución rápida para administración vaginal
PT2772261T (pt) Adsorvente administrado oralmente
SMT201600384B (it) Sicura di una filettatura
DK3357522T3 (da) Coatet medicinsk genstand til lægemiddelsfrigivelse
BR112012015016A2 (pt) formulação farmacèutica e forma de dosagem farmacêutica entérica